0001144204-15-070766.txt : 20151214
0001144204-15-070766.hdr.sgml : 20151214
20151214170518
ACCESSION NUMBER: 0001144204-15-070766
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151210
FILED AS OF DATE: 20151214
DATE AS OF CHANGE: 20151214
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC.
CENTRAL INDEX KEY: 0001137883
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 207273918
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 UNIVERSITY PLAZA DRIVE
STREET 2: SUITE 320
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
BUSINESS PHONE: 201-488-0460
MAIL ADDRESS:
STREET 1: 3 UNIVERSITY PLAZA DRIVE
STREET 2: SUITE 320
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
FORMER COMPANY:
FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 20041122
FORMER COMPANY:
FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC
DATE OF NAME CHANGE: 20030827
FORMER COMPANY:
FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC
DATE OF NAME CHANGE: 20010409
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TAUB MALCOLM S
CENTRAL INDEX KEY: 0001305117
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36641
FILM NUMBER: 151286601
MAIL ADDRESS:
STREET 1: 1350 AVENUE OF THE AMERICAS
CITY: NEW YORK
STATE: NY
ZIP: 10019
4
1
v426885_4.xml
OWNERSHIP DOCUMENT
X0306
4
2015-12-10
0
0001137883
BRAINSTORM CELL THERAPEUTICS INC.
BCLI
0001305117
TAUB MALCOLM S
605 THIRD AVENUE
34TH FLOOR
NEW YORK
NY
10158
1
0
0
0
Common Stock
2015-12-10
4
S
0
12500
2.74
D
51388
D
Common Stock
2015-12-11
4
S
0
980
2.66
D
50408
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.70 to $2.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.65 to $2.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Thomas B. Rosedale (pursuant to power of attorney)
2015-12-14